Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLATI-PARP: Docetaxel, Carboplatin, and Rucaparib in mCRPC with HRD
NCT03442556Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Aug 2018
- Primary completion
- Jun 2025
- Countries
- 1
01
Overview
A Phase 2 trial of rucaparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of Washington. Started Aug 2018; status: terminated.
02
Drugs
rucaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03442556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03442556.